Sangamo Therapeutics (SGMO) Non-Current Receivables (2023 - 2025)
Sangamo Therapeutics has reported Non-Current Receivables over the past 3 years, most recently at $8.9 million for Q4 2025.
- Quarterly results put Non-Current Receivables at $8.9 million for Q4 2025, down 30.22% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (down 30.22% YoY), and the annual figure for FY2025 was $8.9 million, down 30.22%.
- Non-Current Receivables for Q4 2025 was $8.9 million at Sangamo Therapeutics, down from $14.5 million in the prior quarter.
- Over the last five years, Non-Current Receivables for SGMO hit a ceiling of $15.4 million in Q4 2023 and a floor of $8.9 million in Q4 2025.
- Median Non-Current Receivables over the past 3 years was $13.9 million (2025), compared with a mean of $13.2 million.
- Biggest five-year swings in Non-Current Receivables: dropped 16.62% in 2024 and later plummeted 30.22% in 2025.
- Sangamo Therapeutics' Non-Current Receivables stood at $15.4 million in 2023, then dropped by 16.62% to $12.8 million in 2024, then tumbled by 30.22% to $8.9 million in 2025.
- The last three reported values for Non-Current Receivables were $8.9 million (Q4 2025), $14.5 million (Q3 2025), and $14.5 million (Q2 2025) per Business Quant data.